In vitro characterization of GSK2556286 in combination with bedaquiline and pretomanid against Mycobacterium tuberculosis
Rabodoarivelo MS, Galizia J, Recchia D, Stamilla A, Dal Molin M, Hoffmann E, Gaudin C, Eveque M, Ndjogou D, Bailo R, Leding AAM, Simonsson USH, Sanz O, Jiménez E, Bates RH, Degiacomi G, Lucía A, Willand N, Baulard A, Rybniker J, Pasca MR, Ramón-García S; ERA4TB consortium. In vitrocharacterization of GSK2556286 in combination with bedaquiline and pretomanid against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2026 Aug 5;70(8):e0026026. doi: 10.1128/aac.00260-26. Epub 2026 Jul 13. PMID: 42439805; PMCID: PMC13436017.
GSK2556286 (GSK286) is a novel drug candidate with a cholesterol-dependent mode of action that has shown promising in vivo potential to improve tuberculosis treatment when combined with bedaquiline (B) and pretomanid (Pa).
